

Green exfoliation of graphene; an *in vitro* study of toxicity and biocompatibility

Eirini Papanikolaou^{1,2}, Yannis V. Simos^{1,3}, Konstantinos Spyrou^{3,4}, Michaela Patila^{3,5}, Christina Alatzoglou⁵, Patra Vezyraki¹, Konstantinos Tsamis^{1,2}, Dimitrios Gournis^{3,4}, Haralambos Stamatis^{3,5}, Dimitrios Peschos^{1,2}, Evangelia Dounousi²



¹ Laboratory of Physiology, School of Medicine
² Nephrology Department, University Hospital of Ioannina
³ Nanomedicine and Nanobiotechnology Research Group
⁴ Ceramics and Composites Laboratory
⁵ Department of Biological Applications & Technology

INTRODUCTION


Due to their unique physicochemical properties, the use of graphene-based nanomaterials in biomedical applications has attracted great interest over the last decade. Recently, several green exfoliation methods have emerged as more economical and environmentally friendly approaches for producing graphene from graphite. The aim of this study was to evaluate the toxicity and biocompatibility of graphene that has been synthesized either with chemical (Chemical graphene) or green procedures (Biographene).

METHODS

Cytotoxicity of the two compounds was assessed *in vitro* in human THP-1-derived macrophages with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay). Examination of the redox stage of the cells with ROS-DCFDA assay, as well as evaluation of apoptosis and cell cycle analysis, were performed using Flow cytometry.


RESULTS

CELL VIABILITY




In both nanomaterials, toxicity was dose-dependent rather than time-dependent. **Chemical graphene's** exfoliation requires the use of toxic solvent DMF, and thus its toxicity assessment was limited to low doses ($\leq 20 \mu\text{g/mL}$). At these doses both nanomaterials weren't cytotoxic, however **Biographene's** lack of chemicals make it biocompatible even at 10x higher doses ($200 \mu\text{g/mL}$).

REDOX STAGE




None of the two nanomaterials seemed to induce oxidative stress in THP-1 cells, as neither of them generated intracellular reactive oxygen species (ROS) at the doses of 10 and $20 \mu\text{g/mL}$ after 24h of treatment.

INDUCTION OF APOPTOSIS



Both **Biographene** and **Chemical graphene** induced a mild increase of apoptosis in THP-1 cells at doses of 20 and $50 \mu\text{g/mL}$, compared to untreated cells. Elevation in the apoptotic cell population wasn't dose-dependent and was about 5-7%. At these doses, both nanomaterials didn't induce cell necrosis.

CELL CYCLE ANALYSIS



	G0/G1	S	G2/M
Control	44.68 ± 2.09	19.83 ± 1.20	35.49 ± 1.03
Biographene 20 µg/mL	44.63 ± 1.35	19.27 ± 1.50	36.10 ± 3.10
Chemical graphene 20 µg/mL	44.77 ± 2.50	18.41 ± 2.45	36.82 ± 1.57

At the dose of $20 \mu\text{g/mL}$ none of the nanomaterials induced cell cycle arrest at G0/G1 or G2/M phase. This result suggested that no damage in DNA or microtubules occurred after treatment of THP-1 with the two compounds.

CONCLUSION

Although both materials seem to be safe at low doses, green exfoliated- graphene- **Biographene** could be used at higher doses. Moreover, it's sustainable and economical way of production make it an ideal candidate for biomedical applications (i.e., biosensing, drug delivery etc.). Further research on the activation of molecular pathways of inflammation by **Biographene** could prove its value for use in such applications

BIBLIOGRAPHY

- Papanikolaou E, Simos YV, Spyrou K, Tzianni EI, Vezyraki P, Tsamis K, Patila M, Tigas S, Prodromidis MI, Gournis DP, Stamatis H, Peschos D, Dounousi E. Is graphene the rock upon which new-era continuous glucose monitors could be built? Exp. Biology and Medicine. In press (October 2022)
- Simos YV, Spyrou K, Patila M, Karouta N, Stamatis H, Gournis D, Dounousi E, Peschos D. Trends of nanotechnology in type 2 diabetes mellitus treatment. Asian J Pharm Sci. 2021 Jan; 16(1):62-76.
- Riman D, Spyrou K, Karantzas AE, Hrbac J, Prodromidis MI. Glucose sensing on graphite screen-print electrode modified by sparking of copper nickel alloys. Talanta. 2017 Apr;165:466-473.



This research was co-funded by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program of Competitiveness, Entrepreneurship, and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK- 02171)



ECMC
2022

The 8th International Electronic Conference on Medicinal Chemistry
01-30 NOVEMBER 2022 | ONLINE